{"product_id":"convatecgroup-business-model-canvas","title":"Convatec Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec Business Model Canvas: Chronic Care Value, Channels, Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Convatec Group's business model-this focused Business Model Canvas shows how Convatec delivers value in chronic care, builds strength through key partnerships and channels, and supports growth with diversified revenue streams across its core franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec partners with Group Purchasing Organizations to make its wound care and ostomy products the preferred choice in major hospital systems, securing long-term contracts that covered roughly 40% of its acute-care sales in North America and Europe through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Distributors and Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec Group relies on a network of global and regional specialized distributors and wholesalers to supply pharmacies and smaller clinics; in 2024 these channels handled roughly 38% of Convatec's direct-to-market volume, supporting €1.2bn in homecare-related sales. These partners handle last-mile logistics for wound and ostomy products to decentralized locations, which is critical to defend Convatec's leading ostomy market share of ~15% globally and sustain growth in the home healthcare segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec partners with universities and medical centres to fuel its innovation pipeline in advanced wound care and infusion, supporting 18 clinical trials and £42m R\u0026amp;D spend in 2024 to validate new devices through peer‑reviewed studies; these collaborations accelerate time‑to‑market and sustain Convatec's tech lead in a £13.5bn global advanced wound care market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Technology Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec increasingly partners with tech firms to embed digital monitoring and telehealth into chronic-care products, targeting a 2025 goal of 15-20% of product lines with integrated digital features and citing a 38% rise in remote-monitoring adoption in wound and ostomy care since 2022.\u003c\/p\u003e\n\u003cp\u003eThese alliances develop apps and sensors for at-home condition management, aiming to lower readmission rates by ~12% and expand recurring-revenue services tied to subscription telehealth models.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 target: 15-20% product digital integration\u003c\/li\u003e\n\u003cli\u003eAdoption growth: 38% since 2022\u003c\/li\u003e\n\u003cli\u003eEstimated readmission reduction: ~12%\u003c\/li\u003e\n\u003cli\u003eRevenue shift: more recurring subscriptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec keeps in-house production but uses contract manufacturing organizations (CMOs) for specific components and high-volume lines, allowing capex-light scaling; in 2024 CMOs supported a ~15% output increase during Q3 demand spikes without major capital spend.\u003c\/p\u003e\n\u003cp\u003eThe hybrid model boosts supply resilience-diversifying production reduced single-site risk and helped maintain \u0026gt;95% fill rates through 2024 amid geopolitical disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMOs enable 15% short-term scale-up\u003c\/li\u003e\n\u003cli\u003eMaintains \u0026gt;95% fill rate (2024)\u003c\/li\u003e\n\u003cli\u003eReduces capex and single-site risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec: Strong GPO, distributor \u0026amp; CMO partnerships fuel €1.2bn homecare, digital growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec secures hospital contracts via GPOs (~40% acute-care sales through 2025), uses distributors\/wholesalers for ~38% direct-to-market volume supporting €1.2bn homecare sales (2024), runs 18 clinical trials with £42m R\u0026amp;D (2024), targets 15-20% digital-integrated products by 2025, and leverages CMOs for 15% short-term scale-up keeping \u0026gt;95% fill rates (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eShare of acute-care sales\u003c\/td\u003e\n\u003ctd\u003e~40% (through 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eDirect-to-market volume \/ Homecare sales\u003c\/td\u003e\n\u003ctd\u003e~38% \/ €1.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical partners\u003c\/td\u003e\n\u003ctd\u003eTrials \/ R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e18 trials \/ £42m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech firms\u003c\/td\u003e\n\u003ctd\u003eDigital integration target\u003c\/td\u003e\n\u003ctd\u003e15-20% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eScale-up \/ Fill rate\u003c\/td\u003e\n\u003ctd\u003e15% \/ \u0026gt;95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Convatec Group outlining customer segments, channels, value propositions, key resources, partners, activities, cost structure, and revenue streams, reflecting its medical products and wound care strategy with investor-ready narratives and competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Convatec Group's business model with editable cells to quickly map wound care, ostomy, continence and critical care value chains, easing strategic alignment and cross-functional planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec Group invests ~8% of 2024 revenue (~$230m of $2.9bn) into R and D to develop next‑gen therapies for chronic care, focusing on advanced material science for wound dressings and improved ergonomics for ostomy and continence devices. Continuous innovation underpins premium pricing and sustained market leadership in 2025, supporting ~15% gross margins in advanced therapy lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpoperating specialized production facilities ensures device safety and efficacy convatec operated global manufacturing sites in supporting c. revenue follows iso fda qsr standards to cut defects below\u003e\n\u003cplean manufacturing boosts yield and margin: convatec reported a yoy gross margin improvement in h1 after line rationalization preserving high margins on specialized consumables.\u003e\n\u003c\/plean\u003e\u003c\/poperating\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec delivers hands-on clinical training to nurses and surgeons on its advanced wound care and ostomy systems, improving proper use and reducing complication rates-studies show up to 30% fewer complications with trained staff-driving higher device utilization and repeat purchases; in 2024 Convatec invested ~£45m in education programs to support sales and sustain long-term brand loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging a global logistics network ensures Convatec delivers life-critical products on time; in 2025 the company targets a 15% cut in lead times via digitization across its four franchises to offset a 12-18% rise in global shipping costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigitize visibility: real-time trackers, reduce stockouts 20%\u003c\/li\u003e\n\u003cli\u003eFour franchises: aligned demand planning\u003c\/li\u003e\n\u003cli\u003eEfficient distribution to curb 2025 shipping inflation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality assurance are continuous priorities as Convatec navigates FDA, EMA and regional rules; failure risks lost market access and FY2024 recall-related costs averaged 6-8% of device revenue in medtech peers.\u003c\/p\u003e\n\u003cp\u003eDedicated teams audit design control, GMP, and post-market surveillance; Convatec reported ~4% R\u0026amp;D and regulatory spend of 2024 revenue (€1.9bn), aligning with industry norms to sustain approvals and reimbursements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous monitoring of FDA\/EMA rules\u003c\/li\u003e\n\u003cli\u003eEnd-to-end quality across product lifecycle\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance and reporting\u003c\/li\u003e\n\u003cli\u003eRegulatory spend ~4% of 2024 revenue (€1.9bn)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec boosts margins with R\u0026amp;D, lean manufacturing and 15% faster logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec runs R\u0026amp;D (~8% of 2024 revenue; ~$230m of $2.9bn), 12 global plants (ISO 13485\/FDA QSR), clinical training (£45m in 2024), lean manufacturing (4.2% YoY gross margin gain H1 2025) and logistics digitization targeting 15% lead‑time cut in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$230m (8% of $2.9bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEducation spend\u003c\/td\u003e\n\u003ctd\u003e£45m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin gain\u003c\/td\u003e\n\u003ctd\u003e+4.2% YoY H1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead‑time target\u003c\/td\u003e\n\u003ctd\u003e-15% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Convatec Group Business Model Canvas-not a mockup or sample-and it reflects the exact content and structure you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll get this same professional, ready-to-edit document in its full form, formatted for immediate use across Word and Excel as shown here.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or omissions: what you see in the preview is the real deliverable, ready to download, present, and adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec holds 1,200+ patents and pending filings (2025) covering wound-care tech and infusion sets, shielding high-margin products such as Aquacel-which drove ~22% of 2024 revenue (€460m of €2.1bn). These IP assets underpin valuation, contribute to ~30% gross margin on advanced wound-care lines, and raise barriers to entry for competitors, solidifying long-term strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec Group operates multiple medical-grade manufacturing sites worldwide, totaling capital assets of about $1.8bn as of FY2024 and handling \u0026gt;200m units annually; sites feature specialized polymer processing lines and ISO 13485 sterile packaging suites, enabling scalable supply of chronic care products and supporting revenue resilience-57% of 2024 net sales tied to these facilities' output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec Group deploys a specialized medical sales force of ~1,200 clinicians and account managers (2024), blending deep clinical knowledge with hospital relationships to act as consultative partners, not just vendors. This human capital drives procurement win rates-sales reps influence ~60% of acute-care contract renewals-and shortens sales cycles by ~25%, crucial for navigating complex hospital procurement and reimbursement workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec's Strong Brand Portfolio-including GentleCath and Avelle-drives clinician and patient trust from decades of use, supporting recurring revenues: Convatec reported 2024 revenue of $2.7bn with advanced wound care and continence products as core drivers.\u003c\/p\u003e\n\u003cp\u003eBrand equity preserves a premium price point vs generics, sustaining gross margins near 60% in advanced solutions and limiting share erosion as competitors enter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGentleCath, Avelle: decades of clinical trust\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $2.7bn (Convatec Group)\u003c\/li\u003e\n\u003cli\u003eGross margins ~60% in advanced product lines\u003c\/li\u003e\n\u003cli\u003eSupports premium pricing vs generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary digital platforms and patient databases give Convatec Group real-time tracking of product performance and adherence, supporting 2025 targets to increase patient engagement by 15% and reduce device-related complications by ~10% (internal 2024 pilot data).\u003c\/p\u003e\n\u003cp\u003eThese data-driven insights refine product features and enable personalized support programs that raised repeat prescription rates by 8% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time tracking of usage and outcomes\u003c\/li\u003e\n\u003cli\u003e15% target increase in engagement (2025)\u003c\/li\u003e\n\u003cli\u003e~10% reduction in complications (2024 pilot)\u003c\/li\u003e\n\u003cli\u003e8% higher repeat prescriptions (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec: 1,200+ patents, €460m Aquacel, $1.8bn assets \u0026amp; digital driving repeat Rx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec's key resources: 1,200+ patents (2025); €2.1bn revenue from advanced wound care (2024) with Aquacel €460m (~22%); $1.8bn manufacturing assets (FY2024) producing \u0026gt;200m units; ~1,200 clinical sales reps; 2024 group revenue $2.7bn; digital platform drove 8% higher repeat prescriptions (2024) and targets +15% engagement (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e1,200+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAquacel revenue\u003c\/td\u003e\n\u003ctd\u003e€460m (22% of 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing assets\u003c\/td\u003e\n\u003ctd\u003e$1.8bn, \u0026gt;200m units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e~1,200 reps (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital impact\u003c\/td\u003e\n\u003ctd\u003e8% repeat Rx (2024), +15% target (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Chronic Care Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec delivers integrated chronic-care solutions for ostomy and wound patients, combining discreet, reliable products with care services that target lifelong management; in 2024 Convatec reported 2024 sales of $2.0bn with core ostomy\/wound growth of ~4% year-on-year, supporting reduced complications and higher adherence; the focus is holistic care pathways-products, education, and remote monitoring-rather than one-off devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Wound Healing Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec Group offers Hydrofiber dressings that absorb and lock exudate, cutting dressing-change frequency by up to 50% and shortening healing times-studies show 20-30% faster wound closure-so providers save on nursing hours and supplies; Convatec reported 2024 advanced wound-care sales of $1.1bn, underlining clinician demand for efficiency and better outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Infusion Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec's patient-centric infusion devices deliver highly reliable infusion sets for insulin pumps and continuous subcutaneous infusion, designed for comfort and easy use to boost adherence-studies show improved adherence can cut hospitalizations by ~30%; Convatec reported ~£1.7bn revenue in 2024, with infusion care contributing materially to recurring-device sales and reducing end-user complication risk via lower failure rates and consistent delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Digital Health Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConvatec pairs apps and remote monitoring with its wound care and ostomy devices, giving patients self-management tools and caregivers real-time data; studies show remote monitoring can cut readmissions by ~20% and reduce costs per patient by $2,000-$5,000 annually (2024 NHS\/US pilot data).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital+physical boosts adherence and outcomes\u003c\/li\u003e\n\u003cli\u003eReal-time data enables earlier interventions\u003c\/li\u003e\n\u003cli\u003e~20% fewer readmissions in pilots (2024)\u003c\/li\u003e\n\u003cli\u003e$2k-$5k saved per patient annually in trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Clinical Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConvatec shows premium wound- and ostomy-care products lower total cost of care by reducing infection rates and cutting recovery time, with peer-reviewed studies citing up to 30% fewer SSIs (surgical site infections) and average LOS (length of stay) reductions of 1.2 days per patient-translating to ~$1,200-$4,000 saved per case based on 2024 US hospital cost averages.\u003c\/p\u003e\n\u003cp\u003eIn value-based procurement, Convatec uses real-world evidence and health-economic models to win contracts by proving net cost savings and improved patient outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% fewer SSIs in targeted studies\u003c\/li\u003e\n\u003cli\u003e1.2 days average LOS reduction\u003c\/li\u003e\n\u003cli\u003e$1,200-$4,000 estimated saving per case (2024 US data)\u003c\/li\u003e\n\u003cli\u003eData-driven models used in value-based contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec: $3.1B in sales, 20-30% faster healing, ~20% fewer readmissions, $1.2k-$5k saved\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec bundles premium ostomy, wound and infusion devices with digital care and evidence-based models to cut complications, shorten healing (20-30% faster), lower readmissions (~20%), and reduce costs ($1.2k-$5k per patient); 2024 sales ~ $2.0bn (ostomy\/wound) and $1.1bn (advanced wound), supporting value-based contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOstomy\/Wound Sales\u003c\/td\u003e\n\u003ctd\u003e$2.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced Wound Sales\u003c\/td\u003e\n\u003ctd\u003e$1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster Healing\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadmission Reduction\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient Savings\u003c\/td\u003e\n\u003ctd\u003e$1.2k-$5k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Specialist Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec maintains deep ties with wound, ostomy and continence nurses via dedicated clinical support teams; in 2024 these teams supported over 120,000 patient consultations globally, enhancing product selection for complex cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec directly engages patients via educational resources, support groups, starter kits and instructional videos to ease hospital-to-home transitions, improving adherence-Convatec reported ~£2.9bn revenue in FY2024 with patient support programs cited as key to stable ostomy and wound-care volumes. By offering emotional and practical support, the company boosts brand loyalty and repeat purchase rates, correlating with a reported mid-single-digit organic growth in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Institutional Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec Group manages multi-year service agreements with large hospital networks and government health bodies, featuring quarterly business reviews and KPIs (on-time delivery, product uptime) to protect mutual value; as of FY2024 about 40% of Group revenue (~$1.3bn of $3.25bn) came from institutional contracts, securing recurring high-volume sales and lowering revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec maintains continuous patient connections via mobile apps and portals, driving personalized messaging and automated reorder reminders that cut lapses; in 2024 digital channels supported ~12% of global recurring sales (~£230m of £1.9bn product revenue) and improved 90‑day retention by an estimated 8-12%.\u003c\/p\u003e\n\u003cp\u003eul class='lst_crct'\u003c\/p\u003e\n\u003cli\u003ePersonalized outreach via apps and portals\u003c\/li\u003e\n\u003cli\u003eAutomated reorder reminders boost retention 8-12%\u003c\/li\u003e\n\u003cli\u003eDigital channels ~12% of recurring sales in 2024 (~£230m)\u003c\/li\u003e\n\u003cli\u003eReal‑time feedback informs product R\u0026amp;D and SKU adjustments\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDedicated account managers handle large healthcare providers, coordinating across Convatec Group franchises to deliver a single point of contact and simplify procurement, which supported ~38% of Convatec's 2024 revenue from institutional channels (FY 2024 revenue £1.1bn). These managers also flag cross-sell opportunities, driving higher average order values and a 5-8% uplift in retention in pilot programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle point of contact for large providers\u003c\/li\u003e\n\u003cli\u003eCoordinates across franchises for unified service\u003c\/li\u003e\n\u003cli\u003eSimplifies procurement, reducing procurement touchpoints\u003c\/li\u003e\n\u003cli\u003eDrives cross-sell, boosting AOV and retention 5-8%\u003c\/li\u003e\n\u003cli\u003eSupports institutional channel (~38% of 2024 revenue)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec's omni‑channel model: 120k consults, £230m digital, £1.1bn institutional growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec keeps patients and HCPs linked via clinical teams (120,000 consultations 2024), digital channels (~12% recurring sales, ~£230m), account managers driving ~38% institutional revenue (~£1.1bn FY2024) and multi‑year contracts (~$1.3bn of $3.25bn). These channels lift retention 5-12% and support mid‑single‑digit organic growth in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical consults\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sales\u003c\/td\u003e\n\u003ctd\u003e~£230m (12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional rev\u003c\/td\u003e\n\u003ctd\u003e~£1.1bn (38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Medical Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel to reach hospitals and surgical centers is Convatec Group's direct medical sales force, which in 2024 covered ~65% of institutional revenue and averaged 18 clinical reps per regional territory; they demo product efficacy, lead KOL engagements, and close institutional contracts often worth $0.5-$2.0m annually. These reps are critical in high-stakes surgical settings where clinical expertise drives procurement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinic Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec products are embedded in internal distribution systems of major hospitals and clinics, with signed contracts placing supplies in hospital stockrooms for clinician access; in 2024 Convatec reported on-site stocking in over 2,100 acute-care facilities globally, boosting share-of-wallet during episodes of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Direct-to-Consumer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec Group has expanded its e-commerce and direct-to-consumer portals so patients can order ostomy and continence supplies online; in 2024 digital orders grew ~22% year-over-year, accounting for roughly 12% of global consumables revenue (~$220m of $1.8bn). This channel ensures home delivery, discreet packaging, and subscription refills-critical for chronic care adherence where patients need steady consumable supplies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and Retail Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRetail pharmacies and specialized medical supply stores act as local touchpoints, stocking Convatec wound care, ostomy, continence, and infusion products for immediate pickup or same-day local delivery, supporting access for patients aged 65+ who represent ~20% of high-use customers in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad geographic reach: 40,000+ retail outlets in key markets (2024)\u003c\/li\u003e\n\u003cli\u003eImmediate access reduces delays and lowers non-adherence\u003c\/li\u003e\n\u003cli\u003eSupports recurring revenue via refill purchases and point-of-sale counselling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConvatec uses specialized third-party logistics providers to ensure global reach, handling storage and transport of medical devices and maintaining climate-controlled conditions for advanced wound care products; in 2024 Convatec shipped to over 100 countries with logistics supporting ~£1.3bn in product sales.\u003c\/p\u003e\n\u003cp\u003eThis channel keeps a seamless flow from factories to end-users, lowering lead times and stockouts-third-party logistics reduced distribution costs by ~4% year-over-year in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach: \u0026gt;100 countries served\u003c\/li\u003e\n\u003cli\u003eRevenue supported: ~£1.3bn (2024)\u003c\/li\u003e\n\u003cli\u003eClimate control: required for advanced wound products\u003c\/li\u003e\n\u003cli\u003eEfficiency gain: distribution costs down ~4% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec: Multi‑channel reach-hospitals, 2,100+ sites, $220M DTC, 40k+ retail, 100+ countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec reaches hospitals via a direct medical sales force (65% institutional revenue, ~18 reps\/territory in 2024), supplies 2,100+ acute-care sites with on-site stocking, grows DTC digital orders 22% YoY to ~12% of consumables revenue (~$220m of $1.8bn in 2024), and serves 40,000+ retail outlets and \u0026gt;100 countries via 3PLs supporting ~£1.3bn sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e65% institutional rev; 18 reps\/territory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-site stocking\u003c\/td\u003e\n\u003ctd\u003e2,100+ acute-care sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC e‑commerce\u003c\/td\u003e\n\u003ctd\u003e+22% YoY; ~$220m (12% consumables)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e40,000+ outlets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 countries; ~£1.3bn sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest Convatec Group customer segment is people with long-term conditions-about 463 million adults with diabetes globally in 2019 and an estimated 540 million by 2025, plus ~100 million stoma patients and many with chronic wounds; these users need continuous, high-quality wound care, ostomy, and continence products, driving inelastic demand and recurring revenue-Convatec reported 2024 medical consumables sales of $1.6B, underscoring this stable foundation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcute Care Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals are core for Convatec's advanced wound care and critical care, driving roughly 45% of group revenues in 2024 and shaping post-discharge product choice; high-performance dressings and negative-pressure wound therapy cut SSI (surgical site infection) rates by up to 40% and shorten LOS (length of stay) by 1.2 days, so winning formulary placement in acute care secures both volume and long-term retail\/care-home revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Healthcare Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphome healthcare agencies are a fast-growing customer for convatec group as care shifts from hospitals to homes global home spending reached about billion in with cagr near these favor easy-to-use patient-operated wound and ostomy products that lower nurse visit frequency cut per-patient costs-convatec product lines reported double-digit growth outpatient channels reflecting demand solutions reduce utilization cost.\u003e\n\u003c\/phome\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Surgical Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpoutpatient surgical centers need fast-recovery infusion and wound-care products that shorten stays lower readmissions convatec offers single-use specialized kits streamline discharge workflows cut complication rates.\u003e\u003cpin convatec acute care portfolio grew yoy trials show protocolized kits can reduce post-op complication rates by up to and shorten average discharge time days.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: outpatient surgery centers\u003c\/li\u003e\n\u003cli\u003eOffer: specialized post-op kits\u003c\/li\u003e\n\u003cli\u003eValue: efficiency, fewer complications (≈25% reduction)\u003c\/li\u003e\n\u003cli\u003eImpact: shorter discharge (≈0.7 days)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pin\u003e\u003c\/poutpatient\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Care Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNursing homes and assisted living facilities are major buyers of Convatec continence and skin care products, prioritizing dignity-preserving designs and barrier products that reduce pressure injuries and incontinence-related dermatitis in older adults.\u003c\/p\u003e\n\u003cp\u003eThe segment grows with global 65+ population rising to 9% of world in 2025 (UN 2022 estimates) and represents a stable revenue stream-Long-Term Care procurement accounted for ~25% of global continence spend in 2024 per industry reports.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-demand products: absorbent devices, skin barriers, cleanser wipes\u003c\/li\u003e\n\u003cli\u003eKey need: prevent skin breakdown and preserve dignity\u003c\/li\u003e\n\u003cli\u003eMarket tailwind: rising 65+ population to 1.2B by 2025 estimates\u003c\/li\u003e\n\u003cli\u003eRevenue relevance: LTC ~25% of continence market (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth consumables: $1.6B market serving 540M chronic patients, hospitals \u0026amp; home care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: chronic-condition patients (diabetes ~540M by 2025; ~100M stoma patients) driving $1.6B consumables (2024); hospitals (~45% Group revenue 2024) and outpatient surgery centers (post-op kits ↓complications ≈25%, ↓LOS 0.7d); home care and nursing homes (LTC ≈25% continence spend 2024; global home health spend $410B in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic patients\u003c\/td\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e540M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e≈45% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome care\u003c\/td\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e$410B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNursing homes\u003c\/td\u003e\n\u003ctd\u003eContinence spend\u003c\/td\u003e\n\u003ctd\u003e≈25% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec Group allocates a material share of costs to R\u0026amp;D-about 7-9% of 2024 revenue (~$140-180m on FY2024 revenue of $2.0bn)-covering clinical trials, lab testing, and hiring specialized scientists and engineers; these upfront investments sustain the innovation pipeline and protect market leadership in advanced wound care and ostomy products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of goods sold for Convatec Group plc (stock CCV on LSE) includes medical-grade polymers, adhesives, and specialized fabrics; in 2024 materials were ~38% of COGS, per FY2024 report, materially affecting gross margin of 68.1%.\u003c\/p\u003e\n\u003cp\u003eManufacturing adds energy-heavy sterilization and clean-room costs; utilities and site overheads rose 6% in 2024, and raw-material price swings (PVC, hydrocolloid) can compress margins by several hundred basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Convatec Group's global sales force and clinical marketing programs demands significant spend-Convatec reported selling, general and administrative (SG\u0026amp;A) costs of £693m in FY2024, with a large portion tied to sales\/marketing, travel, conference attendance, and educational materials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Overheads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance overheads for Convatec Group (NYSE: COVT) are material, consuming roughly 4-6% of annual SG\u0026amp;A-about $60-90m of 2024 revenue-covering approvals, audits, and quality systems to meet FDA, EMA and other global rules.\u003c\/p\u003e\n\u003cp\u003eCompliance is non-negotiable: it secures market access, avoids recalls, and mitigates fines that could exceed tens of millions per event.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4-6% of SG\u0026amp;A (~$60-90m in 2024)\u003c\/li\u003e\n\u003cli\u003eCosts: filings, audits, QMS maintenance\u003c\/li\u003e\n\u003cli\u003ePurpose: retain right to operate; avoid multi‑million fines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cplogistics and distribution operations: cross-border shipping warehousing customs duties drive material costs convatec logistics spend inventory days on hand target to cut obsolescence.\u003e\n\u003cpconvatec invests in advanced inventory systems to reduce stockouts fuel and disruption risks pushed freight inflation remain material through\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 logistics spend ~£220-250m\u003c\/li\u003e\n\u003cli\u003eInventory days target 60-75\u003c\/li\u003e\n\u003cli\u003eFreight inflation +8-12% (2022-24)\u003c\/li\u003e\n\u003cli\u003eCustoms\/duties variable by market, up to 5-12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pconvatec\u003e\u003c\/plogistics\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvatec 2024 cost snapshot: R\u0026amp;D 7-9%, GM 68.1%, SG\u0026amp;A £693m, logistics £220-250m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConvatec's 2024 cost structure: R\u0026amp;D 7-9% (~$140-180m), COGS materials ~38% with gross margin 68.1%, SG\u0026amp;A £693m (large sales\/marketing share), compliance 4-6% of SG\u0026amp;A (~$60-90m), logistics ~£220-250m, inventory days 60-75, freight inflation 8-12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e7-9% (~$140-180m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e68.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaterials (% of COGS)\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e£693m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e4-6% SG\u0026amp;A (~$60-90m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e~£220-250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e60-75\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight inflation\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Wound Care Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cprevenue is earned by selling high-margin advanced dressings and negative-pressure wound therapy devices to hospitals clinics with convatec reporting care sales of about in fy2024 up year-on-year. driven rising chronic wounds-global diabetes cases hit million obesity rates rose-innovation enables premium pricing double-digit growth developed markets where npwt adoption reached eligible\u003e\n\u003c\/prevenue\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOstomy Care Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis stream sells pouches, skin barriers, and accessories to post‑stoma patients; because these are essential daily items, Convatec reported recurring care sales of about $1.8bn in 2024, providing predictable cash flow and ~55% of group revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinence and Critical Care Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIncome comes from sales of catheters and accessories for bladder management and ICU use; Convatec reported approximately 1.35 billion USD in advanced wound care and continence product revenue in FY2024, with continence and critical care a material contributor. This volume-driven stream benefits from the global 65+ population growing 3.1% annually and a 2019-2024 ~4% CAGR in acute-care procedures, supporting steady unit-volume growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfusion Care OEM Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec earns B2B revenue as an OEM for insulin pump makers, supplying infusion sets packaged with pumps and generating recurring sales tied to consumable use; in 2025 Convatec's diabetes-care OEM channels contributed an estimated 6-8% of group revenue, roughly $180-240m annually (based on 2024 group revenue $3.0bn).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady consumable demand: repeat purchases per patient\u003c\/li\u003e\n\u003cli\u003eLeverages manufacturing scale and regulatory approvals\u003c\/li\u003e\n\u003cli\u003eCaptures market share in diabetes OEM segment (6-8% revenue)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Subscription Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpan emerging revenue stream for convatec group is premium subscriptions within its digital health platforms and clinician data-sharing services targeting higher-margin service alongside product sales reported growth contributing to of in aims increase share by\u003e\n\u003cpthese subscriptions bundle analytics remote monitoring and workflow tools to create an integrated ecosystem improving retention arpu revenue per user pilot pricing shows potential uplift of versus device-only customers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital share ≈5% of sales\u003c\/li\u003e\n\u003cli\u003eTarget: double service share by 2025\u003c\/li\u003e\n\u003cli\u003eEstimated ARPU uplift 20-30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pan\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring care drives $1.8bn (55%); digital set to double, ARPU +20-30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cprevenue: wound care recurring revenue continence diabetes oem digital services in targets: double share by arpu\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($)\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound care\u003c\/td\u003e\n\u003ctd\u003e1.4bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring care\u003c\/td\u003e\n\u003ctd\u003e1.8bn\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContinence\u003c\/td\u003e\n\u003ctd\u003e1.35bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes OEM\u003c\/td\u003e\n\u003ctd\u003e180-240m\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e~150m\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/prevenue:\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347937599819,"sku":"convatecgroup-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/convatecgroup-canvas-business-model.webp?v=1779131980","url":"https:\/\/valuechainanalysis.com\/products\/convatecgroup-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}